Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Final Approval for Difluprednate Ophthalmic Emulsion, 0.05%. Enclosed its press release.
The above information is a part of company’s filings submitted to BSE.